IMPORTANT SAFETY INFORMATION
OMIDRIA must be added to irrigation solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure of phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid,
phenylacetic acid derivatives, and other non-steroidal anti-infl ammatories (NSAIDs), or have a past medical
history of asthma.
The most commonly reported adverse reactions at 2-24% are eye irritation, posterior capsule opacifi cation,
increased intraocular pressure, and anterior chamber infl ammation.
Use of OMIDRIA in children has not been established.
Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation.
You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.
THE LATEST PHARMACOLOGIC
ADVANCE IN CATARACT SURGERY
IS ALSO FULLY REIMBURSABLE.
GET TO KNOW OMIDRIA
®
(phenylephrine and ketorolac injection) 1% / 0.3%
CONTINUOUS THERAPEUTIC EFFECT
THROUGHOUT SURGERY
1
MIOSIS PREVENTION AND
POSTOP PAIN REDUCTION IN ONE
1
FIRST AND ONLY FDAAPPROVED PRODUCT
OF ITS KIND FOR CATARACT SURGERY
1
